A wound care practice billing for the unused portion of a cellular and tissue-based product, commonly called a skin substitute, is working under a rule that changed on January 1, 2026, when CMS eliminated wastage billing for skin substitutes entirely. The enforcement record already shows what happens when a billed graft size diverges from the wound it treated. A practice still billing discarded CTP material, or defending claims from before the change, faces a UPIC or HHS-OIG audit that reaches every claim in the lookback period, not only the claim under review.
The JW and JZ Modifier Framework Before 2026
Medicare's discarded drug policy has required the JW modifier for unused amounts of a single-dose drug or biological since January 1, 2017. CMS added the JZ modifier beginning no later than July 1, 2023, requiring providers to attest that no amount of product was discarded whenever the JW modifier does not apply. Claims missing the required modifier have been returned as unprocessable since October 1, 2023, and CMS expanded the JW requirement again on January 1, 2025 to reach suppliers who discard product during preparation without administering it. For years, skin substitute claims followed this same framework, with practices billing the trimmed or unused portion of a graft as discarded product under the JW modifier.
CMS Reclassifies Skin Substitutes as Incident-to Supplies
The CY 2026 Physician Fee Schedule final rule reclassified most skin substitutes, other than products licensed as biologics, as incident-to supplies rather than drugs or biologicals under Medicare Part B, effective January 1, 2026. Because the JW and JZ modifiers apply only to drugs and biologicals, CMS guidance now states the modifiers are not appropriate for incident-to supplies and that discarded amounts of an incident-to supply are not payable under any circumstance. The same rule cycle set a flat rate of $127.28 per square centimeter and narrowed Medicare coverage from roughly 340 products to 18 evidence-based products nationwide, under updated local coverage determinations adopted by all seven Medicare Administrative Contractors. Our companion piece on Wound Care LCD Compliance details the documentation each covered product now requires.
How Auditors Test the Size-to-Chart Match
The reclassification leaves exposure sitting in claims billed before January 1, 2026. UPIC and HHS-OIG wound care audits reconstruct each claim by comparing the graft size on the invoice, the wound size documented in the procedure note, and the signature log confirming who applied the product and when. A graft billed at 25 square centimeters against a wound measured at 10 square centimeters becomes a finding, and a pattern of oversized ordering across a provider's claim history becomes an extrapolated recoupment demand across the full audit period. Practices navigating prepayment review face the same reconciliation problem; our companion piece on Wound Care Prepayment Review addresses the records that resolve it before a denial becomes a referral.
A graft ordered in the largest available size and billed as wastage against a wound documented at a fraction of that size is the fact pattern that turns a coverage denial into a fraud referral.
Enforcement Already Reaches Skin Substitute Billing
Two recent settlements show what this audit scrutiny produces. DOJ announced in December 2025 that the owners of Apex Medical agreed to pay $309 million to resolve civil False Claims Act liability tied to a scheme that ordered the largest available amniotic membrane allografts regardless of wound size, generating more than $1 billion in alleged false claims; both owners were also sentenced to federal prison for the underlying criminal conduct. In November 2025, DOJ announced a $45 million settlement with Vohra Wound Physicians over allegations that it billed Medicare for medically unnecessary and up-coded debridement procedures across its nationwide nursing-home practice. Both settlements rest on a documented pattern across thousands of claims, the pattern a CTP waste-billing audit is built to find. Our companion piece on Debridement Coding Audits works through the parallel documentation problem in surgical debridement billing.
Why Early Legal Counsel Is Critical
It is critical for wound care practices to promptly retain experienced healthcare defense counsel upon receiving a UPIC records request, an OIG subpoena, or a prepayment review notice tied to skin substitute or CTP billing. Early legal intervention can protect the practice's rights, ensure size and application documentation is presented accurately before the auditor draws conclusions, and preserve defenses specific to claims dated before the rule change. Delaying legal representation can significantly affect the outcome of a matter.
How Health Law Alliance Can Help
Health Law Alliance defends wound care providers and CTP suppliers against UPIC audits, OIG investigations, and False Claims Act exposure tied to skin substitute billing, from the first records request through appeal and litigation. Our bench has overseen 2,000+ audits and handled 5,000+ matters across Medicare and Medicaid program integrity work, background that shapes how we test an auditor's size reconciliation before it hardens into a formal finding. If your practice is facing a CTP wastage audit or a documentation request tied to skin substitute claims, contact us for a free, confidential consultation.
